Literature DB >> 10884300

Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry.

L Beghin1, N Duhal, P Poulain, P Hauw, B Lacroix, J M Lecerf, J P Bonte, J C Fruchart, G Luc.   

Abstract

The measurement of apolipoprotein B (apoB) in purified lipoproteins by immunological assays is subject to criticism because of denatured epitopes or immunoreactivity differences between purified lipoproteins and standard. Chemical methods have therefore been developed, such as the selective precipitation of apoB followed by quantification of the precipitate. In this study, we present the measurement of apoB concentration in lipoproteins purified by ultracentrifugation by combining isopropanol precipitation and gas chromatography/mass spectrometry. Very low density lipoprotein (VLDL; d < 1.006 g/mL); VLDL plus intermediate density lipoprotein (VLDL + IDL; d < 1.019 g/mL); and VLDL, IDL, and low density lipoprotein (VLDL + IDL + LDL; d < 1.063 g/mL) were purified by ultracentrifugation. Apolipoprotein B-100 was selectively precipitated by isopropanol. The leucine content of the pellet was then determined by gas chromatography/mass spectrometry, using norleucine as internal standard. Knowledge of the number of leucine molecules in one apoB-100 molecule makes it possible to calculate the plasma concentration of apoB in the various lipoprotein fractions. ApoB in IDL (d 1.006-1.019 g/mL) and LDL (d 1.019-1.063 g/mL) were then determined by subtracting VLDL-apoB from apoB in lipoproteins d < 1.019 and apoB in lipoproteins d < 1.019 g/mL from apoB in lipoproteins d < 1.063 g/mL, respectively. The isopropanol precipitate was verified as pure apoB (>97%) in lipoprotein fractions isolated from normo- and hyperlipidemic plasma and the method appeared reproducible. The combination of isopropanol precipitation and the GC/MS method appears therefore to be a precise and reliable method for kinetic and epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884300

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.

Authors:  Gouriprassana Roy; Ekaterina Placzek; Thomas S Scanlan
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

2.  LDL binding to lipid emulsion particles: effects of incubation duration, temperature, and addition of plasma subfractions.

Authors:  Nathalie F Chanson; Jean-François Lontie; Annette Gulik; Jacqueline Férézou; Yvon A Carpentier
Journal:  Lipids       Date:  2002-06       Impact factor: 1.880

3.  Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.

Authors:  Dick C Chan; Gerald F Watts; Seng Khee Gan; Esther M M Ooi; P Hugh R Barrett
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

4.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

5.  Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.

Authors:  Mikaël Croyal; Fanta Fall; Véronique Ferchaud-Roucher; Maud Chétiveaux; Yassine Zaïr; Khadija Ouguerram; Michel Krempf; Estelle Nobécourt
Journal:  J Lipid Res       Date:  2016-01-15       Impact factor: 5.922

6.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

7.  Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ1-HDL, α-HDL, and triglyceride-rich lipoproteins.

Authors:  Maud Chétiveaux; Mikaël Croyal; Khadija Ouguerram; Fanta Fall; Laurent Flet; Yassine Zair; Estelle Nobecourt; Michel Krempf
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.